Kearon C
McMaster University, and Hamilton Civic Hospitals Research Centre, ON, Canada.
Semin Thromb Hemost. 1998;24 Suppl 1:77-83.
When the need for surgery arises, temporary interruption of long-term anticoagulation exposes patients to additional thrombotic risk. There is no consensus as to how perioperative anticoagulation should be managed in this setting. Based on an individual assessment of risk factors for arterial or venous thromboembolism and the risk of postoperative bleeding, this review outlines an approach to the perioperative management of anticoagulation that is designed to optimize patient safety and efficient delivery of health care. The duration of interruption of oral anticoagulation is minimized by withholding four daily doses of warfarin before surgery, and by restarting warfarin the same day that surgery is performed. This will usually achieve satisfactory coagulation status intraoperatively (e.g., International Normalized Ratio of 1.5 or less) with a low risk of postoperative bleeding. Supplemental prophylaxis with therapeutic doses of heparin, usually unfractionated heparin, can be reserved for patients with the highest risk of thromboembolism. In the preoperative period, this applies to patients who have had an episode of arterial or venous thromboembolism in the preceding month. In the postoperative period, this approach is generally reserved for patients with an episode of venous thromboembolism in the preceding 3 months, and patients with an episode of arterial embolism in the preceding month who have a low risk of bleeding. Differences in the approach to management of anticoagulation before and after surgery relate to the fact that surgery is an important risk factor for venous, but not arterial, thromboembolism, and that recent surgery greatly increases the risk of anticoagulant-induced bleeding. Subcutaneous unfractionated or low-molecular-weight heparin, in doses recommended to prevent venous thromboembolism in high-risk surgical patients, should be administered to in-patients who have a lesser risk of thromboembolism until oral anticoagulation is reestablished.
当需要进行手术时,长期抗凝治疗的暂时中断会使患者面临额外的血栓形成风险。对于围手术期抗凝治疗应如何管理,目前尚无共识。基于对动脉或静脉血栓栓塞风险因素以及术后出血风险的个体评估,本综述概述了一种抗凝治疗的围手术期管理方法,旨在优化患者安全和医疗保健的有效提供。通过在手术前停用四剂华法林,并在手术当天重新开始使用华法林,可将口服抗凝治疗的中断时间降至最短。这通常会在术中达到令人满意的凝血状态(例如,国际标准化比值为1.5或更低),且术后出血风险较低。对于血栓栓塞风险最高的患者,可保留使用治疗剂量的肝素(通常为普通肝素)进行补充预防。在术前阶段,这适用于前一个月发生过动脉或静脉血栓栓塞事件的患者。在术后阶段,这种方法通常适用于前三个月发生过静脉血栓栓塞事件的患者,以及前一个月发生过动脉栓塞事件且出血风险较低的患者。手术前后抗凝管理方法的差异与以下事实有关:手术是静脉血栓栓塞的重要风险因素,但不是动脉血栓栓塞的重要风险因素,而且近期手术会大大增加抗凝剂引起出血的风险。对于血栓栓塞风险较低的住院患者,应给予皮下注射普通肝素或低分子肝素,剂量为推荐用于预防高危手术患者静脉血栓栓塞的剂量,直至重新建立口服抗凝治疗。